

Is Cardiovascular Disease Preventable?

BERNARD MAN-YUNG CHEUNG

From Department of Clinical Pharmacology, School of Clinical and Experimental Medicine, University of Birmingham, United Kingdom

Cardiovascular disease is the leading cause of death in developed and developing countries. In Asia, heart attacks and stroke are major causes of morbidity and mortality. The risk factors leading to cardiovascular disease are well known.¹ Of these, smoking, blood pressure and cholesterol are the major modifiable risk factors. In highly developed countries such as the United States, we and others have shown that the prevalence of these risk factors is declining.² This is not the case in developing countries.

Cardiovascular diseases form a continuum,³ in which cardiovascular risk factors lead to atherosclerosis, which is not clinically overt at first, but in middle age, may manifest itself as ischaemic heart disease, cerebrovascular and peripheral vascular disease. In old age, accumulated injuries to the myocardium lead to chronic heart failure whereas in the brain, vascular disease is an important cause of senile dementia. The question then arises – can we intervene earlier in the cardiovascular continuum?

Data from the Hong Kong Cardiovascular Risk Factor Prevalence Study showed that hypertension and diabetes are sequelae of obesity.^{4,5} They support the usefulness of the concept of the metabolic syndrome.⁶⁻⁸ Central obesity leads to elevated triglycerides and reduced high density lipoprotein cholesterol. Raised blood pressure and raised blood glucose follow later.^{9,10} This provides a window of

opportunity to prevent cardiovascular disease by preventing the development of the leading risk factors. Numerous studies have shown that lifestyle measures to reduce central obesity will reduce blood pressure and the development of diabetes.¹¹⁻¹³

As a result of economical development, physical activity is declining in Asia.^{14,15} HDL does not decrease with age in American women but it does so in Hong Kong Chinese women.¹⁶ At the same time, a diet that traditionally provides abundant calories for farming and manual labour may be inappropriate for a sedentary lifestyle.¹⁷⁻¹⁹ This may explain the high incidence of diabetes among Asians.

For those who already have cardiovascular disease, medications to modify blood pressure, cholesterol and platelet function have been shown in large clinical trials and meta-analyses to have favourable effects on outcome.²⁰⁻²³ The INTERHEART study has eloquently shown that 90% of heart attacks can be explained by nine risk factors, the majority of which are related to lifestyle and can be modified by changes in lifestyle.²⁴ It is high time we put this knowledge into action.

References

1. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. *Am J Cardiol* 1976; 38: 46-51.
2. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment and control of hypertension among United States adults 1999-2004. *Hypertension* 2007;49:69-75.
3. Cheung BM. The cardiovascular continuum in Asia - a new paradigm for the metabolic syndrome. *J Cardiovasc Pharmacol* 2005;46:125-9.
4. Cheung BM, Wat NM, Man YB, et al. Relationship Between the Metabolic Syndrome and the Development of Hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2). *Am J Hypertens* 2008;21:17-22.

Address for reprints: Prof. Bernard Man-Yung Cheung
Department of Clinical Pharmacology, School of Clinical
and Experimental Medicine, University of Birmingham,
Birmingham, United Kingdom

Received September 29, 2008; accepted October 29, 2008

5. Cheung BM, Wat NM, Man YB, et al. Development of diabetes in Chinese with the metabolic syndrome - a six year prospective study. *Diabetes Care* 2007;30:1430-6.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735-52.
7. Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome --a new worldwide definition. *Lancet* 2005;366:1059-62.
8. Cheung BM, Wat NM, Tam S, et al. Components of the Metabolic Syndrome Predictive of its Development: A Six Year Longitudinal Study in Hong Kong Chinese. *Clin Endocrinol* 2008;68:730-7.
9. Cheung BM. Hypertension as part of the metabolic syndrome. *J Hum Hypertens* 2008 Jun 12. [Epub ahead of print]
10. Cheung BM, Li MF, Ong KL, et al. Raised blood pressure and dysglycemia in Hong Kong Chinese. *Diabetes Care* 2008;31:1889-91.
11. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 1997;20:537-44.
12. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343-50.
13. Lien LF, Brown AJ, Ard JD, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. *Hypertension* 2007;50:609-16.
14. Lam TH, Ho SY, Hedley AJ, et al. Leisure time physical activity and mortality in Hong Kong: case-control study of all adult deaths in 1998. *Ann Epidemiol* 2004;14:391-8.
15. Cheung BM, Thomas GN. The metabolic syndrome and vascular disease in Asia. *Cardiovasc Hematol Disord Drug Targets* 2007;7:79-85.
16. Cheung BM, Li M, Ong KL, et al. High Density Lipoprotein-Cholesterol Levels Increase with Age in American Women but not in Hong Kong Chinese Women. *Clin Endocrinol* 2008. Accepted.
17. Woo J, Cheung B, Ho SC, et al. Influence of dietary pattern on the development of overweight and obesity in a Chinese population. *Eur J Clin Nutr* 2008;62:480-7.
18. Schooling CM, Ho SY, Leung GM, et al. Diet synergies and mortality--a population-based case-control study of 32,462 Hong Kong Chinese older adults. *Int J Epidemiol* 2006;35:418-26.
19. Thomas GN, Cheung BM, Ho SY, et al. Overview of dietary influences on atherosclerotic vascular disease: epidemiology and prevention. *Cardiovasc Hematol Disord Drug Targets* 2007;7:87-97.
20. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002;360:1903-13.
21. Cheung BM, Lauder IJ, CP Lau, et al. Meta-analysis of large randomised controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Brit J Clin Pharmacol* 2004;57:640-51.
22. Cheung BM. Statins for people with diabetes. *Lancet* 2008;371:94-5.
23. Kumana CR, Cheung G, Lauder IJ, et al. Long-term combination therapy with aspirin and clopidogrel. *J Cardiovasc Pharmacol Thera* 2004;9:223-5.
24. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937-52.